Alexander M Spence

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. doi NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies
    Alexander M Spence
    Department of Neurology, University of Washington, Mailstop 356465, 1959 NE Pacific Street, Seattle, WA 98195, USA
    Mol Imaging Biol 11:343-55. 2009
  2. ncbi 2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome
    Alexander M Spence
    Department of Neurology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Clin Cancer Res 8:971-9. 2002
  3. doi NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies
    Alexander M Spence
    Department of Neurology, University of Washington, Box 356465, 1959 NE Pacific Street, Seattle, WA 98195 6004, USA
    Mol Imaging Biol 10:271-80. 2008
  4. doi Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival
    Alexander M Spence
    Department of Neurology, University of Washington, Seattle, Washington 98195, USA
    Clin Cancer Res 14:2623-30. 2008
  5. ncbi Complications of a temozolomide overdose: a case report
    Alexander M Spence
    Department of Neurology, University of Washington School of Medicine, Room RR650, 1959 NE Pacific Street, Seattle, WA 98195, USA
    J Neurooncol 80:57-61. 2006
  6. ncbi Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas
    Alexander M Spence
    Departments of Neurology, University of Washington School of Medicine, Seattle, WA 98195, USA
    J Neurooncol 70:91-5. 2004
  7. ncbi 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter
    Alexander M Spence
    Department of Neurology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    J Nucl Med 45:1653-9. 2004
  8. ncbi Positron emission tomography imaging of brain tumors
    Alexander M Spence
    Department of Neurology, University of Washington School of Medicine, Seattle, WA 98185, USA
    Neuroimaging Clin N Am 13:717-39. 2003
  9. doi Applying a patient-specific bio-mathematical model of glioma growth to develop virtual [18F]-FMISO-PET images
    Stanley Gu
    Department of Bioengineering and Pathology, University of Washington, Seattle, WA 98195, USA
    Math Med Biol 29:31-48. 2012
  10. ncbi [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure
    James G Douglas
    Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA 98195 6043, USA
    Int J Radiat Oncol Biol Phys 64:886-91. 2006

Detail Information

Publications34

  1. doi NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies
    Alexander M Spence
    Department of Neurology, University of Washington, Mailstop 356465, 1959 NE Pacific Street, Seattle, WA 98195, USA
    Mol Imaging Biol 11:343-55. 2009
    ..The goals were to explore the capacity of FLT-positron emission tomography (PET) to distinguish between recurrence and radionecrosis in gliomas and compare the results to those obtained with 2-fluoro-2-deoxy-D: -glucose (FDG)...
  2. ncbi 2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome
    Alexander M Spence
    Department of Neurology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Clin Cancer Res 8:971-9. 2002
    ..Changes in metabolism between the start and finish of RT, and immediate post-RT studies have received little attention...
  3. doi NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies
    Alexander M Spence
    Department of Neurology, University of Washington, Box 356465, 1959 NE Pacific Street, Seattle, WA 98195 6004, USA
    Mol Imaging Biol 10:271-80. 2008
    ..The goal of this study was to prove that the dose of FLT used for positron emission tomography imaging produces no significant toxicity...
  4. doi Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival
    Alexander M Spence
    Department of Neurology, University of Washington, Seattle, Washington 98195, USA
    Clin Cancer Res 14:2623-30. 2008
    ....
  5. ncbi Complications of a temozolomide overdose: a case report
    Alexander M Spence
    Department of Neurology, University of Washington School of Medicine, Room RR650, 1959 NE Pacific Street, Seattle, WA 98195, USA
    J Neurooncol 80:57-61. 2006
    ..This is a report of a 53 year-old man with a glioblastoma multiforme (GBM) treated with an excessive dose of temozolomide (TMZ)...
  6. ncbi Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas
    Alexander M Spence
    Departments of Neurology, University of Washington School of Medicine, Seattle, WA 98195, USA
    J Neurooncol 70:91-5. 2004
    ..The aim of this study was to assess the frequency of response and toxicity in adults with recurrent anaplastic astrocytoma (AA) or glioblastoma multiforme (GM) treated with concurrent continuous TMZ and TMX...
  7. ncbi 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter
    Alexander M Spence
    Department of Neurology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    J Nucl Med 45:1653-9. 2004
    ....
  8. ncbi Positron emission tomography imaging of brain tumors
    Alexander M Spence
    Department of Neurology, University of Washington School of Medicine, Seattle, WA 98185, USA
    Neuroimaging Clin N Am 13:717-39. 2003
    ..As molecular pathways leading to and sustaining neoplasia become better understood, so will our capacity improve to measure them in vivo and intervene to the patient's advantage...
  9. doi Applying a patient-specific bio-mathematical model of glioma growth to develop virtual [18F]-FMISO-PET images
    Stanley Gu
    Department of Bioengineering and Pathology, University of Washington, Seattle, WA 98195, USA
    Math Med Biol 29:31-48. 2012
    ....
  10. ncbi [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure
    James G Douglas
    Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA 98195 6043, USA
    Int J Radiat Oncol Biol Phys 64:886-91. 2006
    ..Based on these premises, we initiated a prospective study of FDG-PET for the treatment planning of radiation dose escalation for the treatment of glioblastoma multiforme...
  11. ncbi Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: compartmental model investigation and mathematical analysis
    Joanne M Wells
    University of Washington, USA
    Mol Imaging 1:151-9. 2002
    ....
  12. pmc Challenges in clinical studies with multiple imaging probes
    Kenneth A Krohn
    Radiology Department, Molecular Imaging Center, University of Washington, Seattle, WA 98195 6004, USA
    Nucl Med Biol 34:879-85. 2007
    ..The purpose of this article is to promote a critical discussion within the molecular imaging community because our future value to the overall biomedical community will be in supporting better treatment outcomes rather than in detection...
  13. ncbi Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas
    Mark Muzi
    Department of Radiology, University of Washington, Seattle, Washington 98195 6004, USA
    J Nucl Med 47:1612-21. 2006
    ..Uptake may result from retention in the biosynthetic pathway or leakage via the disrupted blood-tumor barrier. Visual analysis or static measures of 18F-FLT uptake are problematic as transport and retention cannot be distinguished...
  14. doi Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas
    Kristin R Swanson
    Department of Pathology, University of Washington, Seattle, Washington 98195, USA
    J Nucl Med 50:36-44. 2009
    ..Given the role of hypoxia in upregulating angiogenic factors, we hypothesized that the distribution of hypoxia seen on 18F-FMISO is correlated spatially and quantitatively with the amount of leaky neovasculature seen on T1Gd...
  15. ncbi Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapy
    Michael S Bobola
    Department of Neurological Surgery, University of Washington, 1959 N E Pacific Street, Seattle, WA 98195 6470, USA
    Clin Cancer Res 10:7875-83. 2004
    ..Clin Cancer Res 2002;8:3008.). Here we examine the association of glioma Ap endo activity with clinical response after alkylating agent-based chemotherapy or after radiotherapy...
  16. pmc Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas
    Mindy D Szeto
    Department of Pathology, University of Washington School of Medicine, Seattle, WA 98104, USA
    Cancer Res 69:4502-9. 2009
    ..04). Moreover, highly significant positive correlations were found between biological aggressiveness ratio (rho/D) and both RH (P < 0.00003) and the mean T/B (P < 0.0007)...
  17. ncbi True tracers: comparing FDG with glucose and FLT with thymidine
    Kenneth A Krohn
    Department of Radiology, University of Washington, Seattle, 98195 6004, USA
    Nucl Med Biol 32:663-71. 2005
    ..The fidelity with which analog tracers mimic tracers of the authentic substrate is critically evaluated for [(18)F]-2-fluoro-2-deoxyglucose and [(18)F]-3'-fluoro-3'-deoxythymidine...
  18. ncbi Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging
    Joseph G Rajendran
    Department of Radiology, University of Washington, Seattle, 98195, USA
    Clin Cancer Res 10:2245-52. 2004
    ..Although acute hypoxia results in accelerated glycolysis, cellular metabolism is slowed in chronic hypoxia, prompting us to look for discordance between FMISO and FDG uptake...
  19. ncbi Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond
    David A Mankoff
    University of Washington and Seattle Cancer Care Alliance, Seattle, Washington, USA
    Clin Cancer Res 13:3460-9. 2007
    ....
  20. ncbi Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results
    Joanne M Wells
    University of Washington, USA
    Mol Imaging 1:145-50. 2002
    ..Kinetic analysis of dynamic TdR images was performed to estimate the rate of thymidine transport (K1t) and thymidine flux (KTdR) into brain tumors and normal brain. These estimates were compared to MRI and pathologic results...
  21. ncbi Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation
    Kevin S Tralins
    Department of Radiation Oncology, University of Washington Medical Center, Seattle, Washington, USA
    J Nucl Med 43:1667-73. 2002
    ..On the basis of these premises, we initiated a pilot study to investigate the use of (18)F-FDG PET for the guidance of radiation dose escalation in the treatment of GBM...
  22. pmc Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model
    Christina H Wang
    Department of Pathology, University of Washington, Seattle, Washington 98195, USA
    Cancer Res 69:9133-40. 2009
    ..Such a hybrid tool bridging mathematical modeling and clinical imaging may allow for stratifying patients for clinical studies relative to their pretreatment biological aggressiveness...
  23. ncbi [18F]-2-fluoro-2-deoxyglucose transport kinetics as a function of extracellular glucose concentration in malignant glioma, fibroblast and macrophage cells in vitro
    Robert C Burrows
    Molecular Imaging Research Center, Department of Radiology, University of Washington, 98195, Seattle, WA, USA
    Nucl Med Biol 31:1-9. 2004
    ..The results show that extracellular glucose concentration has a greater impact on the rate of FDG accumulation than the relative abundance of GLUT transporter subtypes...
  24. ncbi What is in a number? The FDG lumped constant in the rat brain
    Kenneth A Krohn
    University of Washington School of Medicine, Seattle, Washington 98195, USA
    J Nucl Med 48:5-7. 2007
  25. ncbi Spontaneously relapsing and remitting primary CNS lymphoma in an immunocompetent 45-year-old man
    Sonia Partap
    Department of Neurology, University of Washington School of Medicine, Seattle, WA 98195, USA
    J Neurooncol 80:305-7. 2006
    ..This case and a handful of others with single remissions emphasize that PCNSL cannot be reliably ruled out by improving or disappearing symptoms, signs or traditional MR imaging abnormalities...
  26. ncbi Paraneoplastic movement disorder in a patient with non-Hodgkin's lymphoma and CRMP-5 autoantibody
    Ali Samii
    Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA
    Mov Disord 18:1556-8. 2003
    ..We report on details of a movement disorder that followed anti-B-cell therapy in a patient with lymphoma, and was accompanied by CRMP-5 IgG...
  27. ncbi Prolonged but reversible migraine-like episodes long after cranial irradiation
    Sonia Partap
    Division of Pediatric Neurology, Children s Hospital and Regional Medical Center, University of Washington, Seattle, WA, USA
    Neurology 66:1105-7. 2006
    ..Whether they all have the same condition is uncertain. Although some had cortical gadolinium enhancement on MRI, all 11 patients returned to baseline over hours to weeks...
  28. ncbi Intracarotid RMP-7 enhanced indocyanine green staining of tumors in a rat glioma model
    Gavin W Britz
    Department of Neurological Surgery, University of Washington, Seattle, USA
    J Neurooncol 56:227-32. 2002
    ....
  29. ncbi The FDG lumped constant in normal human brain
    Michael M Graham
    Division of Nuclear Medicine, Department of Radiology, University of Iowa, Iowa City, Iowa 52242, USA
    J Nucl Med 43:1157-66. 2002
    ..The lumped constant (LC) is a correction factor used to infer glucose metabolic rate (MR(glc)) from FDG metabolic rate (MR(FDG))...
  30. doi External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trial
    Deborah T Blumenthal
    Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute at the University of Utah Health Sciences Center, Salt Lake City, Utah, USA
    Cancer 113:559-65. 2008
    ..Additional objectives included the estimation of response rate, the rate of disease stabilization, and the probability of 1-year survival...
  31. pmc Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme
    Keith J Stelzer
    Celilo Radiation Therapy, Mid Columbia Medical Center, Dalles, OR, USA
    Neuro Oncol 10:88-92. 2008
    ..Steep dose-response curves for both tumor control and neurotoxicity continue to present a challenge to establishing a therapeutic window for fast neutron radiation in GBM, even with modern techniques...
  32. ncbi Central nervous system cancers: Clinical Practice Guidelines in Oncology
    Steven S Brem
    J Natl Compr Canc Netw 3:644-90. 2005
  33. ncbi A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report
    Susan M Chang
    University of California Medical Center, San Francisco, CA 94143, USA
    Invest New Drugs 21:429-33. 2003
    ..To compare two different infusion schedules of phenylacetate (PA) in patients with primary brain tumors and to assess the feasibility of the administration in a multi-institutional setting...
  34. ncbi Bromophenol blue staining of tumors in a rat glioma model
    Tomoko Ozawa
    Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, California, USA
    Neurosurgery 57:1041-7; discussion 1041-7. 2005
    ..Injection of bromophenol blue (BPB) may enhance intraoperative visualization of an infiltrating tumor and its margins and improve the extent of resection. In this study, we investigated the uptake of BPB in experimental rat brain tumors...